FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 7, 2018, Fennec Pharmaceuticals Inc. (the “Company”) held an annual and special meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

1.The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

Name of Nominee Votes For Votes Withheld Broker Non-Votes
Dr. Khalid Islam 9,766,926 795,329 2,451,220
Adrian Haigh 9,767,181 795,074 2,451,220
Chris A. Rallis 9,765,833 796,422 2,451,220
Marco Brughera 10,558,689 3,566 2,451,220
Rostislav Raykov 10,559,584 2,671 2,451,220

2.The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

Votes For 12,999,856
Votes Withheld 13,619
Abstentions
Broker Non-Votes

3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

Votes For 10,293,495
Votes Against 268,760
Abstentions
Broker Non-Votes 2,451,220

4. The resolution to vote for the approval of extension of executive officer options was approved based on the following vote:

Votes For 9,745,451
Votes Against 816,804
Abstentions
Broker Non-Votes 2,451,220


About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.